Kelun Pharmaceutical is mainly engaged in the research and development, production and sales of large infusion series drugs; At the same time, it also produces other dosage forms of drugs (including powder injection, freeze-dried powder injection, small water injection, tablets, capsules, granules and oral liquid) and synthetic raw materials of western medicine. In 2009, the company sold 2.2 billion bottles (bags) of various large infusion products, ranking first in the domestic large infusion industry, with sales exceeding 3.2 billion yuan, with a compound growth rate of 33% in recent three years; In 2009, the company achieved a net profit of 430 million yuan, and the compound growth rate of net profit in the past three years was 565,438+0%. Company 12 dominates the market share of infusion products, ranking first in China. The company has 96 varieties of large infusion products with 2 19 specifications, and 279 varieties of non-large infusion products with 396 specifications, of which 25 varieties of large infusion products and 67 varieties of non-large infusion products are listed in the national essential drugs list. The company has become one of the pharmaceutical manufacturers with the most complete varieties and packaging forms in the infusion industry in China. The scale advantage has brought the benefit advantage, and the gross profit margin of infusion products has reached over 36% in the past few years. At the same time, the company has set up 16 production enterprises in nine provinces and regions across the country, basically forming a national industrial layout.
Advantage 2: technological innovation, the leader of product upgrading.
The company is ahead of other enterprises in the same industry in terms of product upgrading speed and innovation ability, which is the basis for the company to maintain its advantage in the highly competitive large infusion industry and the driving force for the company to ensure its sustainable growth in the future. The company is the first batch of enterprises that successfully developed and listed plastic bottles and soft bags in China. In the increasingly fierce competition of glass bottles, the company accurately grasps the development trend of the industry and takes the lead in upgrading soft plastic packaging (ordinary soft bags+plastic bottles) to replace glass bottles in China.
This company is also the first and only company in China to develop and sell vertical soft bag packaging. Although soft plastic is still the mainstream upgrade variety in the industry, the company has developed a new generation of products-vertical soft bags. Vertical soft bags have all the advantages of soft bags, but the production cost is lower than that of soft bags, close to plastic bottles, and the retail price is slightly lower than that of soft bags and higher than that of plastic bottles. It is also of great value in reducing energy consumption and protecting the environment. It is the most competitive infusion product at present, and has made great contributions to the company's income and profit growth.
The company is also expected to become the first liquid-solid double-cavity bag listed company. The liquid-solid dual-cavity bag is the most advanced ready-to-use infusion product in the world. Because of the high technical requirements, it is only produced in Europe, America and Japan. The company began research and development in 2005, and finally made a breakthrough in technology. Now the installation of equipment has begun.
The company has two national technology R&D centers. Approved by the Ministry of Science and Technology, the company's "National Engineering Technology Research Center for Large-capacity Injections" was included in the first phase project plan of the National Engineering Technology Research Center in 2009. After the joint evaluation by the National Development and Reform Commission of the People's Republic of China, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs and State Taxation Administration of The People's Republic of China, the company was recognized as the "National Enterprise Technology Center".
The R&D company is strong, and Kelun applied for patents 127 (69 invention patents, 52 utility models and 6 designs), of which 70 patents have been authorized (22 invention patents, 42 utility models and 6 designs). Kelun Pharmaceutical Research * * * has obtained 80 certificates and production approvals of various new drugs, among which gatifloxacin tablets and gatifloxacin glucose injection are chemical 1 new drugs. At present, there are 6 1 new drugs in various stages of research and development, among which 27 new drugs are undergoing preclinical research (9 innovative drugs with independent intellectual property rights), 5 new drugs have been declared for clinical use, 17 new drugs have obtained clinical approval, and 12 new drugs have been declared for production.
The third advantage: perfect sales network and strong growth momentum.
Kelun Pharmaceutical sells Kelun products to more than 5,800 dealers at all levels in 57 sales regions across the country. Kelun's sales network effectively covers all provinces and autonomous regions in China, including four municipalities directly under the central government, and indirectly manages more than 4,000 salespeople. Kelun has maintained long-term and stable business relations with 2 150 hospitals above the second level, and maintained 25,000 medical terminal institutions below the second level with dealers at all levels.
The company has a full-time sales service team to provide support and help for each sales area. Combined with the idea that the production base is close to major markets, the company's national sales network improves the sales efficiency of products, which provides a guarantee for continuously improving the market visibility of the company's brands and expanding the market coverage of products.
One of the driving forces of growth: the continuous growth of industry demand, the market brought by soft plastic packaging instead of glass bottles, and the company relies on fund-raising projects to achieve production, occupying more increments. Under the trend of the continuous development of domestic medical and health industry and pharmaceutical market, under the background of the continuous advancement of medical reform and the continuous improvement of medical insurance compensation standards, the large infusion industry can still continue to grow. At the same time, the company will actively participate in the process of "soft plastic packaging replacing glass bottles" being promoted by the industry. The raised funds are mainly used to produce soft plastic packaging products, and the production capacity has been greatly expanded.
The second driving force of growth: leading the continuous upgrading of the product structure of the industry, and the company relies on unique products to seize more market share. If the company is only one of the participants in the process of "soft plastic packaging replacing glass bottles", then the company has turned a new page in product upgrading and become an absolute leader.
The third driving force for growth: the integration opportunity of the industry and the process of improving concentration, the company benefits the most and is the best integrator. With the development of the industry, integration will be put on the agenda, bringing double growth in scale and effect to the company.
The fourth growth driver: began to expand non-infusion products. The company plans to use 17. 13% of the total raised funds to develop non-infusion products, expand the production scale of Zhongnan Kelun and Mingzhu Pharmaceutical, and further strengthen the contribution of non-infusion products to the company's profits.